🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer

RecruitingPhase 2Ages 45 Years - anyFemaleYonsei University
NCT06677944 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In the management of early breast cancer patients, postoperative radiotherapy following breast-conserving surgery has been established as the standard treatment. Over the past two decades, significant changes have occurred in radiotherapy for breast cancer, encompassing dose fractionation methods, radiotherapy techniques, and delineation of the radiation field. Hypofractionated radiotherapy has been reported in numerous randomized phase 3 studies to show equivalent tumor control rates, reduced acute side effects, and similar late side effects compared to conventional fractionation. Among hypofractionated radiotherapy approaches, particularly in early-breast cancer, accelerated partial breast irradiation (APBI) may be chosen over whole breast irradiation (WBI). This approach is based on data indicating that the majority of local recurrences in breast cancer occur around the site of the pr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed ductal carcinoma in situ (DCIS) and invasive breast cancer. * Age ≥ 45 * cT1/cN0, tumor size ≤ 2.5cm * ECOG 0\~2 -ER+, HER2- Exclusion Criteria: * cN+ * Tumor located too close to the skin or chest wall (within 5 mm) * With previous treatment history for breast cancer * Neoadjuvant chemotherapy * Multicentric disease * Diffuse microcalcification * BRCA mutation * Paget's disease * In cases where tumor delineation is not achievable on CT/MRI images
💊

What it tests

  • Preoperative PBI
📍

Where

1 site
Department of Radiation Oncology, Yonsei University College of Medicine
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy